XTAE
ALMD
Market cap8mUSD
Oct 22, Last price
28.70ILS
1D
-1.37%
1Q
-5.28%
Jan 2017
-75.19%
IPO
-98.89%
Name
Allmed Solutions Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
51.12%
Shs. 5Y
-34.08%
Rev. 5Y
16.57%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-14m
L+161,280.26%
CFO
-12m
L+50.55%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Caesarea, Israel, Allium Medical Solutions Ltd. specializes in the creation, manufacturing, and global distribution of advanced, long-term medical stents. These innovative devices are fully covered, designed for expansion, and are retrievable, serving to alleviate various obstructions within the urinary and gastrointestinal (GI) tracts. Their product portfolio encompasses a range of specialized stents, including those for ureteric, bulbar, triangular and round prostatic, and biliary applications.
Key people
Ariel Rubashkin
Chief Executive Officer · since 2019
Shai Tag
Finance Director · since 2019
Erez Keinan
Vice President - Finance · since 2019
Shay Arotchas
Vice President - Operations · since 2013
Ziv Kalfon
Vice President-Engineering & Technology · since 2010
Internal Auditor · since 2007
Director · since 2019
Director · since 2012
David Milch
Director · since 2011
Abraham Nahmias
Chairman of the Board · since 2016
External Director · since 2019
Etan Hillman
External Director · since 2019
Jacob Dagan
Independent Director · since 2016
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||